The funding builds on more than $1.7 million already awarded to the firm, which is building a diagnostic for characterizing patients in clinical trials.
The company aims to commercialize the platform and related services by late 2018.
The SBIR Phase 1 award will go toward developing a test using immuno-PCR technology to detect toxins in medical marijuana.
The company is working with the University of Florida Health Cancer Center to validate its RadTox QuantiDNA test as a monitor of cfDNA in patient plasma.
The company has received grant funding for diagnostic development projects, and is also seeking its first pharma service customers to provide nearer-term revenue.
The funding will go towards developing the PathMap companion diagnostic technology, based on the firm's SnapPath platform.
Proposed increases to small business programs touch off fight between business and research groups, ScienceInsider reports.
The genetic screening firm validated the modifications with a Phase I SBIR grant from NIH and is seeking a Phase II grant to target critical protein domains.
The firm said the method could lead to more studies on the genetic determinants of disease for people of mixed or non-European ethnic backgrounds.
The companies are combining GMSbiotech's proprietary microarray platform with soluble human leukocyte antigen proteins produced by Pure Protein.
23andMe is offering early customers re-testing on newer chips for a fee, Wired reports.
He Jiankui is no longer affiliated with Direct Genomics Biotechnology, the single molecule sequencing company he founded, Nikkei Asian Review reports.
Newsweek writes about the hopes for precision medicine in cancer, but also challenges getting it to patients.
In Genome Research this week: genomic architecture of glioblastoma, predictive computational approach to estimate SNP fitness, and more.